1202070-39-0 Usage
General Description
(R)-1-(5-Fluoropyridin-2-yl)ethanamine hydrochloride is a chemical compound that consists of a chiral amine and a pyridine ring with a fluorine substituent. It is commonly used in the production of pharmaceuticals and agrochemicals, as well as in the preparation of various intermediates for organic synthesis. (R)-1-(5-FLUOROPYRIDIN-2-YL)ETHANAMINE HYDROCHLORIDE is known for its potential as a building block for the synthesis of diverse bioactive molecules, and it is often used as a key starting material in the development of new drug candidates. Additionally, (R)-1-(5-Fluoropyridin-2-yl)ethanamine hydrochloride has been studied for its potential therapeutic applications, including its role in the treatment of neurological disorders and cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 1202070-39-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,2,0,7 and 0 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1202070-39:
(9*1)+(8*2)+(7*0)+(6*2)+(5*0)+(4*7)+(3*0)+(2*3)+(1*9)=80
80 % 10 = 0
So 1202070-39-0 is a valid CAS Registry Number.
1202070-39-0Relevant articles and documents
P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
-
Paragraph 0120; 0125, (2018/02/04)
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor s
Heteroaryl imidazolone derivatives as jak inhibitors
-
, (2012/01/06)
New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
-
Page/Page column 56, (2009/06/27)
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor s
